| 臺大學術典藏 |
2020-04-28T07:11:21Z |
Spatial-dependent mechanical properties of the heel pad by shear wave elastography
|
Lin, C.-Y.; Chen, P.-Y.; Shau, Y.-W.; Tai, H.-C.; Wang, C.-L.; CHE-YU LIN |
| 臺大學術典藏 |
2020-04-28T07:11:21Z |
An Artifact in Supersonic Shear Wave Elastography
|
Lin, C.-Y.; Chen, P.-Y.; Shau, Y.-W.; Wang, C.-L.; CHE-YU LIN |
| 臺大學術典藏 |
2020-04-28T07:11:20Z |
Altered stiffness of microchamber and macrochamber layers in the aged heel pad: Shear wave ultrasound elastography evaluation
|
Wu, C.-H.; Lin, C.-Y.; Hsiao, M.-Y.; Cheng, Y.-H.; Chen, W.-S.; Wang, T.-G.; CHE-YU LIN |
| 臺大學術典藏 |
2020-04-27T08:45:32Z |
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy
|
Leu S.-Y.; Hsieh C.-I.; Tsou M.-H.; Lin C.-Y.; Huang A.T.; Jian J.J.-M.;Cheng S.H.;Tsai S.Y.-C.;Yen K.-C.L.;Chu N.-M.;Chan K.-Y.;Tan T.-D.;Chia-Hsien Cheng;Lin Y.-C.;Leu S.-Y.;Hsieh C.-I.;Tsou M.-H.;Lin C.-Y.;Huang A.T.; Jian J.J.-M.; Cheng S.H.; Tsai S.Y.-C.; Yen K.-C.L.; Chu N.-M.; Chan K.-Y.; Tan T.-D.; CHIA-HSIEN CHENG; Lin Y.-C. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Huang Y.-H.; Lee K.-T.; Wang C.-C.; Chau G.-Y.; Lee W.-C.; Ting C.-T.; Lee P.-H.; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Chia-Hsien Cheng;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-04-21T03:51:56Z |
Ambipolar field-effect transistors by few-layer InSe with asymmetry contact metals
|
Chou, F. C.;Sankar, R.;Ulaganathan, R. K.;Lin, C. Y.; Lin, C. Y.; Ulaganathan, R. K.; Sankar, R.; Chou, F. C. |
| 臺大學術典藏 |
2020-04-20T08:16:03Z |
Zymogen activation, inhibition, and ectodomain shedding of matriptase
|
Lin C.-Y.; Tseng I.-C.; Lin C.-Y.;Tseng I.-C.;Chou F.-P.;Sheng-Fang Su;Chen Y.-W.;Johnson M.D.;Dickson R.B.; Dickson R.B.; Johnson M.D.; Chen Y.-W.; SHENG-FANG SU; Chou F.-P. |
| 臺大學術典藏 |
2020-04-20T08:16:01Z |
Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity
|
Lin C.-Y.; Chen C.-Y.; Tseng I.-C.; SHENG-FANG SU; Wang J.-K.; Johnson M.D.; Gu Y.; Barndt R.; Jia B.; Tseng C.-C.; Tseng C.-C.;Jia B.;Barndt R.;Gu Y.;Chen C.-Y.;Tseng I.-C.;Sheng-Fang Su;Wang J.-K.;Johnson M.D.;Lin C.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:12Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen Y.-C.; Ou D.-L.; Chiun Hsu; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
